Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Genitourin Cancer ; 22(3): 102050, 2024 Feb 14.
Artigo em Inglês | MEDLINE | ID: mdl-38502982

RESUMO

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web of Science databases were performed until December 31, 2022. A meta-analysis was performed following the PRISMA 2020 Guidelines. Of 888 identified articles, full-text screening in 69 articles, there were 26 articles analyzed, with a total of 2314 tumors in 2199 patients, including 418 ACD-RCC tumors in 363 patients, 1340 clear cell RCC (ccRCC) tumors, 308 papillary RCC (pRCC) tumors. Most ACD-RCC patients were male (80.2%). All the ACD-RCC patients underwent prior dialysis with 148.2 months of mean dialysis duration. There were 8.7%, 3.4%, and 5.8% tumors at the T3-4 stage, N1 stage, and M1 stage, respectively. The mean overall survival of ACD-RCC patients was 39.6 months (95% CI, 26.6-52.5). Compared to ccRCC and pRCC, ACD-RCC patients had a longer duration of dialysis (MD: 103.5 and 31.77 months, respectively; 95% CI: [75.48; 131.53] and [0.95; 62.58], respectively), and a higher rate of multifocal tumors (MD: 3.46 and 2.45 tumors, respectively; 95% CI [1.71; 6.98] and [1.26; 4.79], respectively). Regarding genetic characteristics, chromosomes 3 and 16 were the 2 most frequent chromosomal aberrations. The missense mutation in KMT2C (25%) and TSC2 (18.75%) were the 2 most common gene mutations in ACD-RCC. In conclusion, the ACD-RCC subtype exhibited several distinct clinicopathological and genetic characteristics compared to others RCC subtypes. Further researchs are needed to assess the survival outcome and the genetic characteristics of this subtype.

2.
Am J Case Rep ; 24: e942371, 2023 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-38134004

RESUMO

BACKGROUND Esophageal leiomyoma is a rare condition, with an estimated incidence rate of 0.4% of all esophageal neoplasms. These tumors are typically small, rarely more than 5 cm. The treatment depends on symptoms and the size and location of the tumor, with enucleation as the standard treatment of esophageal leiomyomas. Esophagectomy is performed only in very few cases, such as when the tumor is too large, there are multiple leiomyomas, there is a horseshoe shape or circumference, or the tumor is inextricably adhering to the esophageal mucosa. In such complex cases, it is often difficult to perform enucleation. However, with the risks of esophagectomy and intra-thoracic anastomosis, namely reflux, stenosis, leakage, abscess, and infection, attempting to perform enucleation for these cases should still be considered. CASE REPORT We reported a case of a large, multi-lobed, circumferential esophageal thoracoabdominal leiomyoma with successfully performed enucleation and esophageal preservation. A Dor fundoplication and Witzel jejunostomy tube were also performed. Follow-up 3 months postoperatively showed no appearance of reflux or dysphagia. The postoperative esophagogram visualized no obstruction or leakage. Histopathological results gave us concrete evidence of a leiomyoma: elongated cells with eosinophilic cytoplasm and rhomboid nuclei with uniform size. CONCLUSIONS The thoraco-laparoscopic enucleation approach is the method that should be considered first in the treatment of large, multi-lobed, circumferential esophageal leiomyomas, before contemplating esophagectomy and reconstruction.


Assuntos
Neoplasias Esofágicas , Refluxo Gastroesofágico , Laparoscopia , Leiomioma , Humanos , Esofagectomia , Neoplasias Esofágicas/cirurgia , Neoplasias Esofágicas/patologia , Refluxo Gastroesofágico/cirurgia , Leiomioma/cirurgia
3.
World Neurosurg ; 157: e245-e253, 2022 01.
Artigo em Inglês | MEDLINE | ID: mdl-34628034

RESUMO

OBJECTIVE: Esthesioneuroblastoma (ENB) is a rare malignancy of the sinonasal tract and its infrequency has confounded efforts at clearly describing the survival trends associated with this neoplasm over the years. In this study, we reviewed survival trends in ENB and investigated the impact of treatment extent and modality on patient outcomes. METHODS: We accessed the Surveillance, Epidemiology, and End Result (SEER) program to identify ENB cases from 1998 to 2016. A χ2 test was used to compare the categorical covariates and a t test or Mann-Whitney U test was utilized for continuous variables. The impact of prognostic factors on survival was computed using a Kaplan-Meier analysis and multivariate Cox proportional hazards model. We divided ENB patients into 4 periods including 1998-2002, 2003-2007, 2008-2012, and 2013-2016, and investigated survival trends using the Kaplan-Meier curve and log-rank test. RESULTS: ENB patients who underwent biopsy alone were associated with older age, larger tumor diameter, increased rates of tumor extension, nodal/distant metastases, and advanced stages as compared with patients undergoing tumor resection. Our results also demonstrated that surgical resection and adjuvant radiotherapy could confer survival advantages, whereas chemotherapy was associated with reduced survival in patients with ENB. Over the past 2 decades, surprisingly, there has been no change in survival rates for patient with ENB (P = 0.793). CONCLUSIONS: Despite advanced diagnostic studies and modernized treatment approaches, ENB survival has remained unchanged over the years, calling for improved efforts to develop appropriate individualized interventions for this rare tumor entity. Our results also confirmed that surgery and adjuvant radiotherapy is associated with improved patient survival whereas the use of chemotherapy should be considered carefully.


Assuntos
Estesioneuroblastoma Olfatório/mortalidade , Estesioneuroblastoma Olfatório/cirurgia , Cavidade Nasal/cirurgia , Neoplasias Nasais/mortalidade , Neoplasias Nasais/cirurgia , Vigilância da População/métodos , Adulto , Idoso , Estesioneuroblastoma Olfatório/radioterapia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Nasais/radioterapia , Radioterapia Adjuvante/mortalidade , Radioterapia Adjuvante/tendências , Programa de SEER/tendências , Taxa de Sobrevida/tendências
4.
Spectrochim Acta A Mol Biomol Spectrosc ; 77(1): 279-86, 2010 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-20541965

RESUMO

The electronic transitions of the three alpha,alpha'-dihydroxy derivatives of anthraquinone, 1,4-dihydroxy-, 1,8-dihydroxy-, and 1,5-dihydroxy-9,10-anthraquinone (quinizarin, chrysazin, and anthrarufin), were investigated by synchrotron radiation linear dichroism (SRLD) spectroscopy on samples aligned in stretched polyethylene. With synchrotron radiation, polarization data could be determined in the UV region up to ca. 58,000 cm(-1) (7.2 eV), which amounts to an extension by ca. 11,000 cm(-1) (1.4 eV) relative to the range accessible with a conventional light source. Throughout the investigated region (15,000-58,000 cm(-1)), essentially similar wavenumbers, intensities, and transition moment directions were determined for chrysazin and anthrarufin, while the spectrum of quinizarin deviated significantly. The results of time-dependent density functional theory (TD-DFT) calculations were in good agreement with the experimental spectra, leading to the assignment of 10 electronic states for quinizarin, and 8 electronic states for chrysazin and anthrarufin. No evidence was found for contributions from different tautomeric or rotameric forms to the observed spectra.


Assuntos
Antraquinonas/química , Elétrons , Análise Espectral/métodos , Síncrotrons , Modelos Moleculares , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA